PHA advances pulmonary hypertension research to improve lives and accelerate progress toward a cure.
The Pulmonary Hypertension Association is committed to advancing research that improves the lives of people with pulmonary hypertension.
As part of that plan, PHA supports research in the following ways:
Since its founding in 1991, PHA has committed $8 million to support cutting-edge PH research and funded more than 75 researchers. PHA grants support scientists and clinicians who study new methods for early detection and new treatments to prevent the onset of PH.
PHA also advances research through initiatives such as the PHA Registry and the PVDOMICS study. PH health care professionals share their research with peers at events such as PHA’s PHPN Symposium and PHA’s Scientific Sessions.
The Pulmonary Hypertension Association advances research through targeted grant opportunities, funding innovative studies, supporting early-career investigators and promoting collaboration to improve lives and expand knowledge across the PH community.
PHA recognizes past recipients of PHA-funded grants advancing pulmonary hypertension research and improving treatments and patient care.
The Pulmonary Hypertension Association Registry is the largest active, U.S.-based longitudinal PH patient registry. We have approximately 83 PHA accredited PH care centers participating in PHAR with approaching 4,000 enrolled patients. This includes those with PAH, CTEPH, PH-ILD and pediatric PH due to developmental lung disease. The PHAR supports research aimed at improving quality of care, understanding risk factors for patient outcomes and supporting clinical research for new therapies. There are more than 50 research proposals, multiple conference abstracts, and 20 publications using data from PHAR.
The Pulmonary Hypertension Association Registry’s goal is to improve care, find better treatments, and support future research.
Sites that have been accredited by the PH Care Centers initiative and have been approved to enroll patients in PHAR.
The goal of the Pulmonary Hypertension Association Registry is to improve the quality of life and survival of people with pulmonary hypertension.
Advances in Pulmonary Hypertension, the official journal of the Pulmonary Hypertension Association, is the world’s first medical journal dedicated to pulmonary hypertension. The journal is directed by an editorial board of renowned PH experts with the oversight of PHA’s Scientific Leadership Council. Published quarterly online, Advances has readers from 129 countries around the world.
Advances in Pulmonary Hypertension JournalThe PHA International PH Conference and Scientific Sessions
PHA Pulmonary Hypertension Professional Network Symposium
PVDOMICS or pulmonary vascular disease phenomics is a multi-center research initiative led by the National Heart, Lung and Blood Institute in partnership with PHA. The study uses clinical and biological “omics” data across all five pulmonary hypertension classifications to identify new patient subgroups and biological markers that could transform diagnosis, treatment and outcomes.
The observational study included data collection from approximately 1,000 individuals with PH and 500 without PH or at risk for the condition. By examining genetic, molecular and clinical differences among participants, PVDOMICS seeks to improve the accuracy of PH diagnosis and promote more personalized care strategies.
To date, researchers have published more than 20 papers using data from the study. Investigators continue to present findings at scientific and medical conferences, and multiple manuscripts are in development. The project’s long-term goal is to move beyond traditional PH classifications and redefine how PH is categorized and treated.
